The latest price target for Insmed (NASDAQ:INSM) was reported by Truist Securities on February 21, 2025. The analyst firm set a price target for $108.00 expecting INSM to rise to within 12 months (a possible 31.95% upside). 59 analyst firms have reported ratings in the last year.

The latest analyst rating for Insmed (NASDAQ:INSM) was provided by Truist Securities, and Insmed maintained their buy rating.

There is no last upgrade for Insmed

There is no last downgrade for Insmed.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Insmed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Insmed was filed on February 21, 2025 so you should expect the next rating to be made available sometime around February 21, 2026.

While ratings are subjective and will change, the latest Insmed (INSM) rating was a maintained with a price target of $105.00 to $108.00. The current price Insmed (INSM) is trading at is $81.85, which is out of the analyst’s predicted range.